Boehringer Ingelheim and the Case for Staying Private in Pharma

The best argument against listing a pharmaceutical company is that Boehringer Ingelheim has never needed to. Drug development is the archetypal long-horizon, high-failure, capital-intensive activity, which is exactly the profile that public markets price poorly and patient private owners price well. This case study closes the chemicals and life sciences pillar of the Germany Company Stories hub and contrasts with the Merck KGaA hybrid structure.

Why is private ownership well suited to pharmaceuticals?

Because the cash flow profile of drug development is the opposite of what public markets reward. A programme consumes capital for a decade with a high probability of failure, and the value created is invisible until late-stage data arrives.

A listed company facing that profile is under permanent pressure to demonstrate progress, which biases decisions toward assets that generate readouts rather than assets with the best expected value. It also creates pressure to in-license late-stage compounds at high prices to fill near-term gaps.

A private owner with no reporting obligation can terminate a failing programme quietly, continue funding a promising one through an ambiguous phase, and decline to comment on either. Those three freedoms are worth a great deal in an industry where the cost of persisting with a bad asset and the cost of abandoning a good one are both enormous.

The constraint is that all of this depends on the business generating enough cash to fund itself, which requires an existing commercial franchise. Private ownership works for a company that is already large; it cannot create one.

What does the animal health business contribute?

Diversification and cash stability. Animal health has a shorter development cycle, lower regulatory cost per product and demand driven by pet ownership and livestock production rather than by healthcare reimbursement systems.

That combination produces steadier cash flow than human pharmaceuticals, which is precisely what a self-funding research organisation needs. The division effectively underwrites part of the human pharmaceutical research budget.

It also demonstrates a portfolio principle that applies far beyond pharmaceuticals: pair a high-variance, high-return activity with a lower-variance business that shares capability, and the combination can sustain investment through the variance.

The capability overlap is genuine rather than financial. Formulation science, manufacturing, regulatory expertise and distribution transfer between the two, which is what distinguishes this from unrelated diversification of the kind the Siemens breakup unwound.

How do private pharmaceutical companies handle patent cliffs?

With the same difficulty as everyone else, but with more time. A patent expiry removes revenue abruptly regardless of ownership, and the response, replacing it with new products, takes years that a listed company often does not have before investor patience runs out.

The private advantage is that a revenue decline can be absorbed without a share price collapse triggering management change. The company can accept several years of lower profitability while a new franchise matures, provided the balance sheet supports it.

The private disadvantage is acquisition capacity. Filling a revenue gap through a large acquisition requires either cash or shares, and a private company has only the first, which limits the size of transaction available exactly when it is needed most.

The practical consequence is that private pharmaceutical companies tend to buy earlier-stage assets and partnerships rather than commercial-stage companies, accepting more scientific risk in exchange for affordability.

What governance does a large private pharmaceutical company need?

More, not less, because the external mechanisms are absent. The substitutes are a professional supervisory body with genuine independent membership, a family shareholder framework defining distribution policy and decision rights, and disclosure discipline that exceeds legal requirements.

Many large German private companies voluntarily publish financial reports to a standard close to listed requirements. The reason is practical: bond investors, banks, partners and regulators all need to assess the company, and voluntary transparency lowers the cost of capital.

The family framework matters most as the shareholder base grows across generations. Rules on distributions, on family employment and on the transfer of interests need to be settled and enforced, since these are what prevent a liquidity demand from one branch forcing a strategic change.

The underlying principle is the same as in the governance pillar: ownership structures survive when they anticipate conflict, and fail when they assume goodwill.

Is Germany a good place to run a pharmaceutical company?

For research and manufacturing, largely yes. For pricing and commercialisation, increasingly not, and the difference explains why German pharmaceutical companies generate a disproportionate share of revenue abroad.

The strengths are real: a deep chemistry and biology research base, clinical infrastructure, strong regulatory expertise and a manufacturing supply chain that includes the equipment and materials specialists described in the hidden champions analysis.

The pressures are on price and on energy. European reimbursement systems negotiate prices well below American levels, so the commercial return on a successful drug is concentrated in a single foreign market, which creates its own political risk. Energy costs affect manufacturing though less severely than in bulk chemistry.

The practical response across the industry has been to keep research and specialist manufacturing in Germany while building commercial and clinical presence where the revenue is, which is a stable configuration provided the research base is maintained.

What should a private company owner take from this model?

That staying private is a strategy requiring active maintenance rather than a default. Boehringer's independence rests on a distribution policy that keeps most profit inside the company, a governance framework that survives generational transfer, and businesses that generate enough cash to fund the ambition.

Remove any one and the model fails. A family that raises distributions cannot fund research. A family without governance rules fragments. A business without a cash engine cannot self-finance.

The second point is honesty about the ceiling. Private ownership caps the size of transaction the company can execute, which means accepting that certain competitive positions are unavailable. Owners who want both independence and unlimited scale eventually get neither.

For a CFO advising a family group, the useful framing is to quantify what independence costs: the transactions foregone, the growth rate ceiling and the diversification the family cannot achieve. If the family still chooses independence with that number in front of them, the structure will hold.

How do private companies of this size raise debt?

Through bond markets and bank facilities, which requires exactly the disclosure a private company might prefer to avoid. Large private issuers typically publish audited financial statements and maintain credit ratings, giving bond investors information comparable to listed peers.

The practical result is that the privacy is partial. What the company avoids is not disclosure but the specific pressures of equity markets: quarterly guidance, analyst expectations, share price reaction to clinical data and the takeover threat.

That distinction is worth drawing precisely, because owners frequently justify staying private on confidentiality grounds when the actual benefit is decision-making freedom. A company that needs debt will disclose regardless.

The financing constraint that remains is equity. Debt capacity is bounded by cash flow and by the family's tolerance for leverage, which is generally conservative, so the total capital available for a transaction is far smaller than a listed peer of similar size could raise.

How does a private company attract senior executives?

With cash, tenure and autonomy rather than equity. The absence of stock options removes the largest component of pharmaceutical executive compensation elsewhere, and the substitutes are long-term cash incentive plans, phantom equity tied to internal valuation, and considerably longer effective tenure.

That trade attracts a specific type of executive: one who values the ability to run a decade-long strategy over the possibility of a large equity outcome in three years. For research leadership in particular, that selection effect is favourable.

It is less favourable in commercial and digital functions, where the competitive market for talent is priced on equity upside and where private companies routinely lose candidates to listed peers and to biotechnology firms offering options.

The structural answer used by several large private groups is a synthetic long-term incentive tracking internal enterprise value, which reproduces the economics of equity without issuing any. It is administratively complex and it works.

What happens if the family eventually wants liquidity?

The options narrow to three: a partial listing, a sale of a division, or an internal market allowing family members to sell interests to each other or to the company. Each has been used somewhere in German industry.

The internal market is the least disruptive and requires a valuation mechanism the family trusts, usually an independent periodic valuation with defined transfer windows. Without it, a single member needing liquidity can force a discussion about the whole structure.

A partial listing solves liquidity permanently and imports exactly the pressures the private model exists to avoid, which is why families that go this route usually use a structure preserving control, such as the KGaA form.

Divisional sale is the option that damages the model most, because it typically removes the stable cash generator that funds the research, and the sequence rarely reverses.

What can a mid-sized company copy from this model?

The distribution discipline, which is the mechanism doing most of the work. A company retaining the substantial majority of its profit for decades accumulates a research and investment capacity that a peer distributing half its earnings simply cannot match, regardless of ownership form.

The second copyable element is portfolio design: pair the volatile activity with a business that shares capability and produces steadier cash, rather than holding unrelated assets for financial diversification.

The third is disclosure discipline without market exposure. Publishing to a high standard for lenders, partners and employees builds credibility and lowers financing cost while preserving the freedom that private ownership provides.

Frequently Asked Questions